Skip to main content
Log in

A decade of change

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Indexed number of active substances entering each phase of development from 2001 to 2009.
Figure 2: Probability of success to market from key milestones.
Figure 3: Changes in the percentage of lead projects in each development phase between 2001 and 2010 by asset origin.
Figure 4: R&D budgets in 2010 for top spenders.
Figure 5: Changes in therapeutic area focus from 2001 to 2010, for new drugs in all stages from Phase I trials to submission.

References

  1. Lamattina, J. The impact of mergers on pharmaceutical R&D. Nature Rev. Drug Discov. 10, 559 (2011).

    Article  CAS  Google Scholar 

  2. Slatko, J. The future belongs to biologics. Med Ad News 16, 34 (2010).Article

    Google Scholar 

  3. Arrowsmith, J. Trial watch: Phase II failures: 2008–2010. Nature Rev. Drug Discov. 10, 328–329 (2011).Article

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arrowsmith, J. A decade of change. Nat Rev Drug Discov 11, 17–18 (2012). https://doi.org/10.1038/nrd3630

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3630

  • Springer Nature Limited

This article is cited by

Navigation